1. Home
  2. NRIX vs MATW Comparison

NRIX vs MATW Comparison

Compare NRIX & MATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • MATW
  • Stock Information
  • Founded
  • NRIX 2009
  • MATW 1850
  • Country
  • NRIX United States
  • MATW United States
  • Employees
  • NRIX N/A
  • MATW N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • MATW Metal Fabrications
  • Sector
  • NRIX Health Care
  • MATW Telecommunications
  • Exchange
  • NRIX Nasdaq
  • MATW Nasdaq
  • Market Cap
  • NRIX 750.4M
  • MATW 721.1M
  • IPO Year
  • NRIX 2020
  • MATW 1994
  • Fundamental
  • Price
  • NRIX $16.85
  • MATW $24.45
  • Analyst Decision
  • NRIX Strong Buy
  • MATW
  • Analyst Count
  • NRIX 14
  • MATW 0
  • Target Price
  • NRIX $26.29
  • MATW N/A
  • AVG Volume (30 Days)
  • NRIX 1.8M
  • MATW 339.8K
  • Earning Date
  • NRIX 10-09-2025
  • MATW 11-20-2025
  • Dividend Yield
  • NRIX N/A
  • MATW 4.08%
  • EPS Growth
  • NRIX N/A
  • MATW N/A
  • EPS
  • NRIX N/A
  • MATW N/A
  • Revenue
  • NRIX $83,687,000.00
  • MATW $1,497,689,000.00
  • Revenue This Year
  • NRIX $58.48
  • MATW N/A
  • Revenue Next Year
  • NRIX N/A
  • MATW N/A
  • P/E Ratio
  • NRIX N/A
  • MATW N/A
  • Revenue Growth
  • NRIX 48.32
  • MATW N/A
  • 52 Week Low
  • NRIX $8.18
  • MATW $18.50
  • 52 Week High
  • NRIX $23.09
  • MATW $32.24
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 80.15
  • MATW 55.77
  • Support Level
  • NRIX $12.43
  • MATW $24.14
  • Resistance Level
  • NRIX $13.43
  • MATW $25.70
  • Average True Range (ATR)
  • NRIX 0.97
  • MATW 0.85
  • MACD
  • NRIX 0.32
  • MATW 0.13
  • Stochastic Oscillator
  • NRIX 98.68
  • MATW 46.58

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About MATW Matthews International Corporation

Matthews International Corp is a personal services company that provides brand solution services, memorialization products, and industrial products in the United States and Europe. The majority of Matthews' revenue is derived from its SGK Brand Solutions business, which provides brand development services, printing equipment, creative design services, and embossing tools to the consumer packaged goods and packaging industries. The company's Memorialization segment, which sells bronze and granite memorials, caskets, and cremation equipment to the cemetery and funeral home industries, also contributes an important amount. Maximum amount of Matthews' revenue is generated from sales made in the North America, while European customers also contribute a sizable percentage.

Share on Social Networks: